GDF15 and Cachexia: A newly published Phase 2 trial of ponsegromab, a GDF‐15 inhibitor, implements this approach by showing improvement in digital measures of daily physical activity in cancer cachexia patients, as well as increases in weight gain, appetite and skeletal muscle mass [33].